Interestingly, the risk of progression from CHIP to MDS to AML is significantly heterogeneous among the patients despite the fact that the precursor states of MDS and AML are associated with similar gene mutations conferring a clonal advantage [15, 16]. This evidence concerns the gene STUB1 and myelodysplastic syndrome.